Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
For Q1 FY27, Ipca Laboratories reported consolidated revenue of ₹2,788 crores, an increase of 21% from ₹2,309 crores in Q1 FY26. The consolidated EBITDA margin also improved to 22.88% from 18.39% in the prior year's comparable quarter. Domestic formulation revenue grew by 13% to ₹1,082 crores, and export revenue saw a significant increase of 34% to ₹603 crores.
Ipca Laboratories has revised its FY27 revenue growth guidance upward to a range of 14%-16%, an increase from the previous guidance of 12%-13%. The company also raised its consolidated EBITDA margin guidance to 23%, up from the earlier projection of 22%.
At the 76th AGM held on August 13, 2026, all proposed resolutions were passed. This included the adoption of the audited financial statements for the year ended March 31, 2026, the declaration of a dividend, and the re-appointment of directors Ajit Kumar Jain, Pranay Godha, and Prashant Godha as Executive Directors for a five-year term starting August 16, 2026. Shareholder approval was also given for the remuneration of cost auditors for the 2026-27 financial year.
As of September 18, 2026, the daily and weekly technical trends for Ipca Laboratories are indicated as bullish, with the Supertrend indicator at 1837.91 on a daily basis and 1619.76 on a weekly basis. Key price levels to monitor include immediate resistance near ₹2010.23 and support around ₹1974.07.
As of 18 Sept 2026, 03:30 pm
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Primary driver: Price swings are higher than typical
The session opened materially above the previous close, indicating a sharp repricing at the open.
The move may reflect new information; subsequent price follow-through is worth monitoring.
Trading volume was unusually high, but the closing price did not show a clear directional move.
This indicates increased participation without a clear directional signal.
Trading activity was substantially higher than usual and the price closed higher.
This may reflect stronger-than-usual market participation; follow-through and relevant company or market news merit review.
Latest complete financial results for Q1 FY27 and comparative quarterly trends.
| Metric | Q1 FY2026-27(Latest) | Q4 FY2025-26 | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 |
|---|---|---|---|---|---|
| Revenue From Operations | PEAK₹2,788.10 crore | ₹2,388.48 crore | ₹2,392.50 crore | ₹2,556.50 crore | ₹2,308.85 crore |
| Finance Costs | ₹11.88 crore | PEAK₹20.20 crore | ₹17.62 crore | ₹19.61 crore | ₹18.51 crore |
| Profit Before Exceptional Items And Tax | PEAK₹572.08 crore | ₹450.27 crore | ₹428.33 crore | ₹449.84 crore | ₹330.51 crore |
| Profit Before Tax | PEAK₹572.08 crore | ₹404.45 crore | ₹445.98 crore | ₹391.58 crore | ₹330.51 crore |
| Tax Expense | PEAK₹149.27 crore | ₹95.05 crore | ₹81.93 crore | ₹108.08 crore | ₹96.09 crore |
| Profit Loss For Period | PEAK₹424.27 crore | ₹306.69 crore | ₹363.67 crore | ₹280.53 crore | ₹232.89 crore |
The company reported higher revenue and significantly higher profit for the quarter ended 30 June 2026 compared to the same period last year. Revenue from operations increased by 20.76 percent year-on-year to ₹2,788.10 crore. Profit for the period rose by 82.18 percent to ₹424.27 crore. The faster profit growth was supported by a reduction in finance costs.
The quarter ended 30 June 2026 saw revenue increase by over 20 percent year-on-year, while profit for the period grew by 82.18 percent. The profit improvement was supported by lower finance costs and, on a sequential basis, the absence of an exceptional loss that had affected the previous quarter. Earnings per share increased by 72.36 percent year-on-year.
Exchange disclosures and regulatory announcements for Ipca Laboratories.
Ipca Laboratories reported Q1 FY27 consolidated revenue of INR2,788 crores, up 21% from INR2,309 crores in Q1 FY26. Consolidated EBITDA margin improved to 22.88% from 18.39%. The company revised its FY27 revenue growth guidance upward to 14%-16% from 12%-13%, and consolidated EBITDA margin guidance to 23% from 22%. Domestic formulation revenue grew 13% to INR1,082 crores, and export revenue grew 34% to INR603 crores.
Ipca Laboratories Limited uploaded the transcript of its earnings or quarterly call on August 17, 2026, at 17:00:00. The call concluded on August 14, 2026, at 16:15:00, following prior intimation to the exchange on August 6, 2026. The transcript is available for review at https://www.ipca.com/shareholders-information-conference-calls-concall-transcripts/.
Ipca Laboratories Limited reported that all resolutions proposed at its 76th Annual General Meeting held on August 13, 2026, were passed by the requisite majority. The meeting approved the adoption of audited financial statements for the year ended March 31, 2026, declared a dividend, and secured re-appointments for directors Ajit Kumar Jain, Pranay Godha, and Prashant Godha as Executive Director with remuneration for a five-year term starting August 16, 2026. Additionally, shareholders ratified the remuneration payable to cost auditors M/s. ABK & Associates for the 2026-27 financial year, with voting conducted via remote e-voting between August 10 and 12, 2026.
Ipca Laboratories Limited submitted an audio link for its conference call held on August 14, 2026, to discuss the company's Q1 FY27 earnings and business update. The filing was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and addressed to BSE Ltd. and NSE India Limited under scrip code IPCALAB. The communication was digitally signed by Harish P. Kamath, Corporate Counsel & Company Secretary, on August 14, 2026.
Ipca Laboratories Limited, Solid Stone Company Limited, Candour Techtex Limited, Sundaram Multi Pap Limited, ITI Limited, and JSW Cement Limited approved their unaudited financial results for the quarter ended June 30, 2026, during Board meetings held on August 13, 2026. Bank of India took physical possession of a residential property in Boisar, Palghar, on August 7, 2026, from borrower Mr. Aryan Ajay Panchal to recover a secured debt of Rs. 1,12,41,225.57 under the SARFAESI Act. Additionally, Sundaram Multi Pap Limited announced its 32nd Annual General Meeting will be conducted via video conference on September 29, 2026.
Ipca Laboratories Ltd. filed standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, as approved by the Board on August 13, 2026. Standalone revenue from operations was ₹2,119.24 crores, up from ₹1,746.90 crores in the same quarter last year, with net profit at ₹373.29 crores versus ₹262.04 crores. Consolidated revenue from operations was ₹2,788.10 crores, up from ₹2,308.85 crores, and consolidated net profit after tax rose to ₹422.81 crores from ₹234.42 crores. The auditors issued an unmodified report on both the standalone and consolidated results. The Board also resolved on June 26, 2026 to amalgamate Krebs Biochemicals & Industries Ltd., with an appointed date of April 1, 2026, pending approvals, and no effect was recorded in these results.
Ipca Laboratories Limited held its 76th Annual General Meeting via video conference on August 13, 2026, to approve audited financial statements for the year ended March 31, 2026, and declare a dividend. The meeting agenda included the appointment of directors Ajit Kumar Jain and Pranay Godha by rotation, the re-appointment of Executive Director Prashant Godha with remuneration, and the ratification of cost auditor fees. E-voting was conducted between August 10 and 12, 2026, with results to be declared after scrutiny by Ms. Jigyasa N. Ved.
Recent market and company developments associated with Ipca Laboratories.
The Indian stock market is expected to open quietly on September 18, following mixed global cues. The Sensex ended slightly down, while the Nifty 50 was modestly up. Analysts suggest monitoring key resistance and support levels as geopolitical concerns persist.
At the same time, the fund is evaluating hospital expansion, hybrid diagnostics businesses and valuations to identify healthcare companies capable of sustaining growth.
Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector.
As rising global bond yields and escalating US-Iran tensions loom, the Indian stock market braces for a negative open. Analysts suggest a cautious approach with stock-specific strategies, identifying potential buy opportunities amid the chaos.
Market expert Raja Venkatraman shares his top stock picks for 18 August. Here’s his technical outlook and trade strategy.
Stock Market Live Updates: We are in the second half of the day's trade, and the markets are looking to mark a recovery from the day's low. The markets are under pressure, as indices trade lower at the beginning of a new week. The Nifty is down nearly 80 points, falling below the 24,300 mark. Infosys, Tata Motors PV and HCLtech are top losers.
Emkay Global Financial, Ipca Laboratories, buy, Recommendations
Ipca Laboratories, Ipca Laboratories shares, Ipca Laboratories Q1 FY27 results, Ipca Laboratories share price, Ipca Laboratories target price, Ipca Laboratories stock, pharma stocks, pharmaceutical stocks, JM Financial, Nuvama Institutional Equities, Motilal Oswal Financial Services, Ipca Laboratories Buy rating, Ipca Laboratories revised target price, Ipca Q1 results, Ipca Laboratories earnings, Unichem Laboratories, pharma sector, stock ma
Comprehensive Section Breakdown for Ipca Laboratories
Strategic Vision: Manufactures and supplies active pharmaceutical ingredients and formulations.
• Integrated manufacturing of APIs and formulations
• Broad portfolio of products across multiple therapeutic areas
• Extensive international distribution network
Revenue from operations rose by ₹399.62 crore, or 16.73 percent, compared to the immediately preceding quarter ended 31 March 2026. On a year-on-year basis, the increase was ₹479.25 crore, representing a 20.76 percent rise from the quarter ended 30 June 2025.
The sequential increase follows two quarters where revenue had remained relatively stable, at ₹2,392.50 crore in the December 2025 quarter and ₹2,388.48 crore in the March 2026 quarter. The current quarter’s revenue of ₹2,788.10 crore marks a clear step up from that level.
Profit before tax increased by 73.09 percent year-on-year, rising from ₹330.51 crore to ₹572.08 crore. Profit for the period grew by 82.18 percent, from ₹232.89 crore to ₹424.27 crore.
A notable factor in the sequential comparison involves exceptional items. In the quarter ended 31 March 2026, profit before exceptional items was ₹450.27 crore, while profit before tax was ₹404.45 crore, indicating an exceptional loss of approximately ₹45.82 crore. In the current quarter, profit before exceptional items and profit before tax were identical at ₹572.08 crore, meaning no such exceptional charges were recorded. The absence of that loss contributed to the sharper rise in reported profit relative to the previous quarter.
The major expense items for the quarter ended 30 June 2026 included cost of materials consumed at ₹638.14 crore, employee benefit expense at ₹601.56 crore, and other expenses at ₹719.68 crore. Depreciation and amortisation amounted to ₹110.81 crore.
Finance costs declined both sequentially and year-on-year. They fell by 41.19 percent from ₹20.20 crore in the previous quarter to ₹11.88 crore. Compared to the same quarter last year, finance costs decreased by 35.82 percent from ₹18.51 crore. This reduction in financing charges contributed to the improvement in pre-tax profit.
Tax expense increased by 55.34 percent year-on-year, from ₹96.09 crore to ₹149.27 crore. Because profit before tax grew at a faster rate, the effective tax rate moved from approximately 29.1 percent in the prior-year quarter to 26.1 percent in the current quarter.
Basic earnings per share from continuing operations rose to ₹15.84, up 72.36 percent from ₹9.19 in the same quarter last year. The paid-up value of equity share capital remained unchanged at ₹25.37 crore throughout the period.
Category: Manufacturing
The company develops and produces a wide range of formulations and APIs, catering to various therapeutic areas such as pain management, rheumatology, antimalarials, and hair care.
Key Products & Services: Azifast • Azibact • Bisotrol • Bronchosolvin • Calchek • Cardoz • Cartiflex • Celedol • Clarbact
Core Thesis: The company leverages its integrated manufacturing capabilities to produce a diverse portfolio of pharmaceutical products for global markets.
• Integrated Manufacturing: The company maintains formulation facilities in several Indian states, enabling the production of both APIs and finished formulations. • Global Market Reach: IPCA's products are distributed internationally across the Americas, Africa, Asia, Australia, and Europe. • Diverse Therapeutic Areas: The company caters to a wide range of therapeutic areas including pain management, rheumatology, antimalarials, and hair care.